Breast Tumor Ablation Study Parameters To Be Reviewed By FDA Panel
This article was originally published in The Gray Sheet
Executive Summary
Clinical trial criteria for studying percutaneous breast tumor removal devices will be explored by FDA's General & Plastic Surgery Devices Panel during a July 24 meeting in Gaithersburg, Md
You may also be interested in...
Hemostatic Agent Downclassification Should Await Guidance – Panel
FDA plans to develop a draft guidance document for absorbable hemostatic agent 510(k) submissions and submit it for panel review before reconsidering downclassification of the devices
Endocare Gains Clearance For Benign Breast Tumor Therapy; Malignant Next
Endocare will follow up its FDA 510(k) clearance of the Visica minimally invasive cryoablation system for benign breast tumors with a submission for malignant tumors.
Dr Reddy's Strengthens Russian OTC Portfolio Through Glenmark Deal
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from India's Glenmark.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Medtech Insight?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: